Orphan Drugs
Europe · 2 shared keywords
Updated
Reviewed by Vidhi Upadhyay
Europe AI in Drug Repurposing Market Industry Trends and Forecast to 2034: Segmented by (Approach, Indication, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$439.8 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $81.3 Mn | — | — |
| 2025 (base) | $98.2 Mn | +$16.9 Mn | — |
| 2026 (forecast) | $118.6 Mn | +$20.4 Mn | +20.8% |
| 2027 (forecast) | $143.3 Mn | +$24.7 Mn | +45.9% |
| 2028 (forecast) | $173.1 Mn | +$29.8 Mn | +76.3% |
| 2029 (forecast) | $209.1 Mn | +$36.0 Mn | +112.9% |
| 2030 (forecast) | $252.6 Mn | +$43.5 Mn | +157.2% |
| 2031 (forecast) | $305.2 Mn | +$52.5 Mn | +210.7% |
| 2032 (forecast) | $368.7 Mn | +$63.5 Mn | +275.4% |
| 2033 (forecast) | $445.3 Mn | +$76.7 Mn | +353.5% |
| 2034 (forecast) | $538.0 Mn | +$92.6 Mn | +447.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $98.2 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $538.0 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 20.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Artificial Intelligence in Drug Repurposing |
| Segments | Approach and indication (see all) |
| Key players | BenevolentAI, Healx, Insilico Medicine, Recursion Pharmaceuticals, Every Cure (see all) |
| Regulator in Europe | EMASource: European Medicines Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
AI in drug repurposing searches data to find new uses for existing medicines, cutting the time and cost of development.
Key segments of the AI in Drug Repurposing market include approach (Knowledge Graphs, Machine Learning on Omics and Real-World Data Mining) and indication (Rare Diseases, Oncology and Infectious Diseases).
Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Drug Repurposing market. Health systems are moving from pilots to wider use.
Generative AI, automation of paperwork and AI tools approved as medical devices give the AI in Drug Repurposing market strong growth, including in emerging health systems.
Concerns about accuracy, bias, privacy and liability, along with unclear regulation and the cost of fitting AI into clinical workflows, hold back the AI in Drug Repurposing market.
The AI in Drug Repurposing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).[1] In the countries we cover here, medicines are approved by ANSM (France)[2], BfArM (Germany)[3], AIFA (Italy)[4], Ministry of Health (Russia)[5], AEMPS (Spain)[6], MHRA (UK)[7], CBG-MEB (Netherlands)[8], FAMHP (Belgium)[9], Swissmedic (Switzerland)[10], Läkemedelsverket (Sweden)[11], Danish Medicines Agency (Denmark)[12], URPL (Poland)[13] and TITCK (Turkey)[14]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.[15]
[1] European Medicines Agency. Checked 14 Nov 2026.
[2] ANSM, French medicines agency. Checked 14 Nov 2026.
[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.
[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
[8] Medicines Evaluation Board (CBG-MEB). Checked 19 Nov 2026.
[9] Federal Agency for Medicines and Health Products (FAMHP). Checked 19 Nov 2026.
[10] Swissmedic. Checked 19 Nov 2026.
[11] Swedish Medical Products Agency (Läkemedelsverket). Checked 19 Nov 2026.
[12] Danish Medicines Agency. Checked 19 Nov 2026.
[13] Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL). Checked 19 Nov 2026.
[14] Turkish Medicines and Medical Devices Agency (TITCK). Checked 19 Nov 2026.
[15] European Commission, health technology assessment. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for AI in Drug Repurposing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.
What doctors and scientists are doing in AI in Drug Repurposing right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Europe · 2 shared keywords
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Europe · 1 shared keyword
Digital Health · Europe
Digital Health · Europe
Digital Health · Europe
Digital Health · Europe
Digital Health · Europe
Digital Health · Europe